Αποτελέσματα Αναζήτησης
1 Ιουλ 2020 · Pathological Discussion. Dr. Amy Ly: Histologic evaluation of the biopsy specimen revealed invasive ductal carcinoma, grade 2, spanning at least 1.6 cm in greatest dimension. No definitive...
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Evolution and prognostic significance of HER-2 conversion...
- 20-Year Risks of Breast-Cancer Recurrence After Stopping Endocrine Therapy at 5 Years
During the study period from 5 to 20 years, the absolute...
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
The 21-gene recurrence-score assay (Oncotype DX, Genomic...
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
The RASTER (Microarray Prognostics in Breast Cancer) study...
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
1 Ιουλ 2020 · In this review article, we try to shed a light on various cancer-causing factors, type of cancer, how the cancer starts, sign or symptom of cancer, diagnosing tests, the treatments of...
1 Ιαν 2011 · In this case study, a women aged 40 was diagnosed with Metastatic breast cancer. Metastatic breast cancer is a complex multi-stage disease involving the expansion of cancerous cells from...
Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain. Timothy E. Guiney, M.D., Mathew S. Lopes, M.D., Mannudeep K. Kalra, M.D., Meghan J. Mooradian, M.D., Tomas G. Neilan, M.D.,...
25 Σεπ 2019 · Figure 1. Initial Imaging Studies of the Chest, Obtained before the Lung Cancer Diagnosis. A biopsy specimen of the lung mass showed evidence of lung adenocarcinoma with a mutation in KRAS.
11 Μαρ 2018 · We report a case of advanced stage metastatic malignant melanoma of the scalp with a durable (31 months) response to ipilimumab immunotherapy. This is the first case study reporting long-term, progression-free response to ipilimumab in metastatic melanoma without side effects of therapy.
Our topics are comprehensive, encompassing new understandings of cancer diagnosis, tumor biology, and treatment decisions. We also welcome tumor board reports which showcase multidisciplinary discussions of illustrative cases within a defined tumor group.